CP-COV03 / Hyundai Bioscience - LARVOL DELTA

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Trial of CP-COV03, a Host-Directed Antiviral for Dengue and Dengue-like Illnesses (IDWeek 2026) - No abstract available

Clinical • P2/3 data • Dengue Fever • Infectious Disease

A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2) (clinicaltrials.gov) - P2/3 | N=210 | Recruiting | Sponsor: Hyundai Bioscience Co., Ltd.

New P2/3 trial • Dengue Fever

Translational potential of safe-by-design nanoengineered niclosamide in viral and cancer therapy. (PubMed, Mater Today Bio) - "This study presents a comprehensive evaluation of the long-term biocompatibility of CP-COV03 (NIC-MgO-HPMC), a nanohybrid formulation of niclosamide designed to overcome its limitations in solubility, stability, and bioavailability. The absence of systemic toxicities validates CP-COV03 as a scalable and biocompatible therapeutic platform suitable for extended dosing regimens. By combining durable safety with enhanced drug performance, CP-COV03 offers strong translational potential for persistent viral infections, including long COVID, future pandemic threats, and oncology applications."

Journal • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Oncology

A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19. (PubMed, Nat Commun) - "Secondary endpoints, including time to sustained symptom resolution, time to return to usual health, and reduction in hospitalization risk, also showed favorable results in the CP-COV03 group compared to placebo. These findings indicate that CP-COV03 is a safe and effective therapeutic option for the treatment of mild to moderate COVID-19 and represents a promising advancement in the repurposing of niclosamide through nanohybrid engineering."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Efficacy of CP-COV03 (a niclosamide-based inorganic nanohybrid product) against severe fever with thrombocytopenia syndrome virus in an in vitro model. (PubMed, Microbiol Spectr) - "This result is comparable to other antiviral drugs used against viruses like severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We believe that our study makes a significant contribution to the literature as our findings suggest that CP-COV03 may serve as a potential treatment for SFTS, highlighting its importance in the field of antiviral research."

Journal • Preclinical • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Thrombocytopenia

"@MBOrtigoza #ASMmicrobe2023 #CPCOV03 #COVID19 #Xafty" (,@CoinJw)

Infectious Disease • Novel Coronavirus Disease

Clinical And Virological Efficacy Of A Potential Pan-antiviral Agent, Cp-cov03 In Covid-19 Infection (ASM Microbe 2023) - "BackgroundRecently, Niclosamide's anti-viral activity against various types of viruses including SARS-CoV2 and the underlying mechanisms were identified in vitro. In terms of safety, most of the adverse events were mild and there were no serious adverse events.ConclusionAs a results, CP-COV03 showed clinical efficacy and rapid virus elimination. Considering the observed clinical outcomes, virus reduction, and safety, CP-COV03 is considered to be a promising candidate for the treatment of COVID-19.$$table_{92B9B953-DDD4-4307-870A-8EA5C8A61757}$$"

Clinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

An oral antiviral drug from Korea may be a problem solver for COVID-19 (PRNewswire) - "...Dr. Jin-Ho Choi, a Chief Scientist of its major shareholding bio tech company CNPharm and Chair Professor at Dankook University, presented the study...at the 20th Science Council of Asia (SCA) Conference held in Guangzhou, China, on May 13th. The presentation included the efficacy test results and related data from CP-COV03...According to the in vivo study that compared viral loads in the blood of the control group and treated groups, the control group exhibited its viral load in the blood to be recorded the highest on the 3rd day of infection and started to decrease from the 4th day, while all five treated groups recorded the lowest level on the same day....This study may be the world's first in vivo evidence for anthelminthic Niclosamide to be repurposed as an antiviral drug in oral formulation."

Preclinical • Infectious Disease • Novel Coronavirus Disease